EULAR review maps a crowded field of COVID-19 immunomodulators and separates signal from noise
A sweeping systematic review for the European League Against Rheumatism has pulled together the early evidence on immunomodulatory therapies used to treat SARS-CoV-2 infection. The analysis was designed to inform EULAR points to consider on COVID-19 pathophysiology and treatment from a rheumatology perspective, and it landed on a familiar but clinically important conclusion: some agents appear useful in defined patient groups, while much of the therapeutic field still rests on thin or conflicting evidence.
The review screened 60,372 records and included 401 articles. Two reviewers independently applied a Population, Intervention, Comparator and Outcome framework and extracted data on efficacy and safety across the full spectrum of SARS-CoV-2 illness, from early infection to severe disease. Risk of bias was assessed with validated tools, and the resulting evidence base proved uneven. Many studies were observational or otherwise vulnerable to confounding, and even among randomized trials the number of studies per drug was often small.
One sentence captures the central problem: the evidence is abundant in volume, but sparse in certainty.
Glucocorticoids emerge as the clearest survival signal in severe COVID-19
Among the treatments reviewed, glucocorticoids offered the most persuasive evidence of benefit. Randomized trial data indicated a mortality reduction in specific subsets of patients, consistent with the biology of severe COVID-19, where dysregulated host inflammation can drive lung injury, hypoxemia, and multiorgan dysfunction. In that setting, dampening the immune response is not merely symptomatic care; it can interrupt the inflammatory cascade that turns viral pneumonia into life-threatening respiratory failure.
The review does not turn glucocorticoids into a universal remedy. Benefit appeared in particular subsets, not across every stage of infection or every clinical phenotype. Early disease can be dominated by viral replication, where broad immunosuppression may be less useful or potentially counterproductive. Later disease, especially in patients with severe inflammatory manifestations, is where the balance shifts toward anti-inflammatory treatment and away from unrestrained immune activation.
That distinction matters at the bedside because the same drug can be biologically helpful in one phase and less compelling in another. In a rapidly evolving infection, timing and phenotype shape the therapeutic effect as much as the drug itself.
Hydroxychloroquine failed to show benefit at any stage of infection
The review is equally direct about hydroxychloroquine. Across 12 randomized controlled trials, the drug did not demonstrate benefit at any disease stage. This is the kind of clean negative result that matters in a crowded therapeutic space, because it closes off one more plausible but unsupported strategy and spares clinicians from treating speculation as evidence.
Mechanistically, hydroxychloroquine drew attention early because of its immunomodulatory and antiviral properties in vitro. Clinical trial data, however, did not translate those laboratory hypotheses into meaningful patient benefit. The gap between cell culture and bedside outcomes is not unusual in infectious disease, but COVID-19 produced an especially vivid example of how preliminary pharmacology can outpace clinical proof.
Tocilizumab and other agents produced mixed, incomplete results
Evidence for tocilizumab was conflicting. Four randomized controlled trials were available, but they did not yield a single, settled answer. That pattern leaves room for the drug’s use in selected patients, yet it also prevents simple generalization across the full hospitalized population. Cytokine blockade may help when hyperinflammation is dominant, but if the underlying inflammatory state is not the main driver of deterioration, an interleukin-targeted strategy may add little.
Other agents were represented by only a handful of trials, limiting what can responsibly be concluded. Randomized data were available for convalescent plasma, interferon beta, and intravenous immunoglobulin, with two trials each. Single trials were identified for anakinra, baricitinib, colchicine, leflunomide, ruxolitinib, interferon kappa, and vilobelimab. Some of these studies produced interesting results, but the review treats them as preliminary rather than practice-defining.
A single positive trial can be hypothesis-generating without being practice-changing.
Baricitinib plus remdesivir adds one more piece to the evolving treatment puzzle
Among the single-trial signals, baricitinib combined with remdesivir was positive. The finding is biologically plausible: baricitinib can blunt inflammatory signaling, while remdesivir targets viral replication. In combination, the two drugs address different phases of the illness process, which may matter in patients whose disease sits at the intersection of viral activity and mounting inflammation.
Still, one positive trial does not settle the matter. Combination therapy can outperform monotherapy when the disease mechanism is layered and dynamic, but the review does not supply enough replicated evidence to make broad claims beyond that signal. The finding supports further study rather than immediate therapeutic certainty.
Why the review calls for steroid-plus-immunomodulator trials
The most actionable recommendation from the review is the call for randomized trials comparing glucocorticoids alone versus glucocorticoids plus anticytokine or immunomodulatory treatment. That proposal follows directly from the evidence pattern. Glucocorticoids already appear to improve survival in some patients, so the key question is whether an additional agent can improve on that foundation without adding unacceptable toxicity, secondary infection risk, or immunosuppressive burden.
In clinical terms, the issue is not whether inflammation matters. It clearly does in severe COVID-19. The question is how much incremental benefit remains after standard corticosteroid treatment, and which patients are most likely to benefit from a second immune-directed drug. The review leaves that question open because current data are too fragmented to answer it with confidence.
Safety data were also part of the evaluation, but the heterogeneity of the included studies and the variable risk of bias limited how far those data could be pushed. Different agents bring different adverse-effect profiles, and trial quality affects how reliably harms can be detected. A small or methodologically weak study can miss uncommon but serious events, particularly when therapies alter immune function in patients who are already medically fragile.
The evidence base is broad, but many decisions still rest on limited trial data
The review’s strength is breadth. It gathers the principal immunomodulatory strategies tested early in the pandemic and organizes them into a framework that rheumatologists and other clinicians can actually use. Its weakness is also clear: many of the therapies are supported by only one or a few randomized trials, and the certainty of evidence remains uneven across the field.
For now, the data support a practical hierarchy. Glucocorticoids stand out as the most credible survival-improving intervention in defined subsets of patients with COVID-19. Hydroxychloroquine does not earn a place in treatment on the basis of these trials. Tocilizumab and several other immunomodulators remain in a zone of partial signal and unresolved uncertainty, where additional randomized evidence is still needed before firm conclusions can be drawn.
The review does not close the book on immune-directed therapy for SARS-CoV-2 infection. It narrows the field to the treatments with the strongest rationale and the least equivocal data, while leaving the rest where they belong for now: in carefully designed trials, not in assumptions.